← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

APM logoAptorum Group Limited(APM)Earnings, Financials & Key Ratios

APM•NASDAQ
$0.85
$5M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryVaccines and Infectious Disease
AboutAptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.Show more
  • Revenue$0-100.0%
  • EBITDA-$4M+62.6%
  • Net Income-$4M-51.1%
  • EPS (Diluted)-0.78-25.8%
  • ROE-31.43%-29.1%
  • ROIC-18.29%+65.9%
  • Debt/Equity0.28+25.7%
  • Interest Coverage-25.84+70.5%
Technical→

APM Key Insights

Aptorum Group Limited (APM) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Trading at only 0.4x book value

✗Weaknesses

  • ✗Weak Piotroski F-Score: 1/9
  • ✗Weak momentum: RS Rating 19 (bottom 19%)
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Shares diluted 20.6% in last year
  • ✗Trading more than 30% below 52-week high
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

APM Price & Volume

Aptorum Group Limited (APM) stock price & volume — 10-year historical chart

Loading chart...

APM Growth Metrics

Aptorum Group Limited (APM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-84.8%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM79.65%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM82.83%

Return on Capital

10 Years-61.09%
5 Years-73.99%
3 Years-79.69%
Last Year-25.03%

APM Peer Comparison

Aptorum Group Limited (APM) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
CASI logoCASICASI Pharmaceuticals, Inc.Direct Competitor2.33M0.15-0.06-15.77%-183.93%-301.8%11.96
ZLAB logoZLABZai Lab LimitedDirect Competitor2.32B21.01-13.1315.33%-38.15%-22.81%0.31
NVAX logoNVAXNovavax, Inc.Direct Competitor1.53B9.363.6964.69%-14.73%
AEYE logoAEYEAudioEye, Inc.Direct Competitor95.09M7.66-30.6414.52%-7.63%-47.8%0.15
AYTU logoAYTUAytu BioPharma, Inc.Direct Competitor16.08M2.56-1.191.84%-39.02%-172.12%1.21
CLOV logoCLOVClover Health Investments, Corp.Direct Competitor1.37B2.68-15.7640.34%-2.58%-17.08%
HCM logoHCMHUTCHMED (China) LimitedProduct Competitor2.31B13.4361.05-24.8%77.53%46.37%0.12
CNTB logoCNTBConnect Biopharma Holdings LimitedProduct Competitor137.84M2.48-8.86-220.08%-80.44%0.00

Compare APM vs Peers

Aptorum Group Limited (APM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CASI

Most directly comparable listed peer for APM.

Scale Benchmark

vs IQV

Larger-name benchmark to compare APM against a more recognizable public peer.

Peer Set

Compare Top 5

vs CASI, ZLAB, NVAX, AEYE

APM Income Statement

Aptorum Group Limited (APM) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Sales/Revenue0383.45K535.17K911.51K1.54M1.3M431.38K0
Revenue Growth %--39.57%70.32%69.17%-15.95%-66.71%-100%
Cost of Goods Sold58.9K318.01K794.54K1.01M1.46M1.22M420.81K255.05K
COGS % of Revenue-82.93%148.47%111.35%94.68%93.83%97.55%-
Gross Profit
-58.9K▲ 0%
65.44K▲ 211.1%
-259K▼ 495.8%
-104K▲ 59.8%
81.85K▲ 178.7%
80.06K▼ 2.2%
10.57K▼ 86.8%
-255K▼ 2513.4%
Gross Margin %-17.07%-48.4%-11.41%5.31%6.18%2.45%-
Gross Profit Growth %-211.1%-495.79%59.85%178.71%-2.19%-86.8%-2513.4%
Operating Expenses5.63M10.39M-259K20.17M19.29M17.25M10.61M3.54M
OpEx % of Revenue-2710.65%-48.4%2213.03%1250.91%1331.33%2460.02%-
Selling, General & Admin2.88M6.73M10.78M7.71M8.03M7.97M4.42M1.47M
SG&A % of Revenue-1755.38%2014.14%845.63%520.56%614.59%1023.46%-
Research & Development2.5M3.1M6.94M11.59M10.87M9.22M5.2M1.94M
R&D % of Revenue-808.71%1296.61%1271.19%704.93%711.42%1204.98%-
Other Operating Expenses257K-9.77M-17.98M877K392K68.95K999K128K
Operating Income
-5.69M▲ 0%
-10.33M▼ 81.4%
-18.2M▼ 76.2%
-19.89M▼ 9.3%
-19.21M▲ 3.5%
-17.51M▲ 8.8%
-10.6M▲ 39.5%
-3.8M▲ 64.2%
Operating Margin %--2693.44%-3400.44%-2182.63%-1245.59%-1351.01%-2457.47%-
Operating Income Growth %--81.42%-76.2%-9.32%3.46%8.84%39.45%64.19%
EBITDA-5.63M-9.65M-16.9M-18.56M-18.01M-16.3M-9.48M-3.54M
EBITDA Margin %--2515.51%-3157.53%-2036.17%-1168.22%-1257.8%-2196.68%-
EBITDA Growth %--71.2%-75.19%-9.83%2.94%9.51%41.87%62.63%
D&A (Non-Cash Add-back)58.9K682.29K1.3M1.33M1.19M1.21M1.13M255.05K
EBIT-2.56M-10.68M-16.42M5.16M-27.02M-11.53M-10.6M-4.01M
Net Interest Income0-4.46M-3.7M-244K-93.6K146.59K-121K-147K
Interest Income44.27K0000146.59K00
Interest Expense04.46M3.7M243.63K93.6K0121.14K146.92K
Other Income/Expense3.13M-4.81M-1.92M0-7.91M5.98M6.26M-361K
Pretax Income
-2.56M▲ 0%
-15.13M▼ 490.7%
-20.12M▼ 32.9%
4.92M▲ 124.5%
-27.11M▼ 651.1%
-11.53M▲ 57.5%
-4.34M▲ 62.3%
-4.16M▲ 4.2%
Pretax Margin %--3946.8%-3759.02%539.76%-1758.37%-889.27%-1006.31%-
Income Tax-14.05K0000000
Effective Tax Rate %0.55%0%0%0%0%0%0%0%
Net Income
-2.55M▲ 0%
-14.83M▼ 482.3%
-18.69M▼ 26.0%
7.07M▲ 137.8%
-25.05M▼ 454.4%
-9.8M▲ 60.9%
-2.83M▲ 71.2%
-4.27M▼ 51.1%
Net Margin %--3868.04%-3491.81%775.31%-1624.38%-756.17%-654.88%-
Net Income Growth %--482.33%-25.99%137.82%-454.44%60.88%71.17%-51.08%
Net Income (Continuing)-2.56M-15.13M-20.12M4.92M-27.11M-11.53M-4.34M-4.16M
Discontinued Operations00000000
Minority Interest-14.04K-368.53K-1.51M-3.68M-6.1M-7.88M-9.46M-9.36M
EPS (Diluted)
-0.85▲ 0%
-5.31▼ 524.7%
-6.40▼ 20.5%
2.00▲ 131.3%
-7.15▼ 457.5%
-2.75▲ 61.5%
-0.62▲ 77.5%
-0.78▼ 25.8%
EPS Growth %--524.71%-20.53%131.25%-457.5%61.54%77.45%-25.81%
EPS (Basic)-0.85-5.31-6.402.03-7.15-2.75-0.62-0.78
Diluted Shares Outstanding3.01M2.79M2.9M3.15M3.5M3.57M4.52M5.45M
Basic Shares Outstanding3.01M2.79M2.9M3.11M3.5M3.57M4.52M5.45M
Dividend Payout Ratio---10.69%----

APM Balance Sheet

Aptorum Group Limited (APM) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Total Current Assets20.28M28.72M8.03M33.66M12.69M7.07M2.48M959.55K
Cash & Short-Term Investments18.22M13.02M6.25M31.88M8.5M1.99M2.01M874.24K
Cash Only16.25M12.01M5.19M3.5M8.13M1.88M2.01M874.24K
Short-Term Investments1.97M1.01M1.06M28.38M236.62K102.48K00
Accounts Receivable179.49K990.85K487.59K341.06K3.56M1.18M70.94K4.54K
Days Sales Outstanding-943.17332.55136.57842.9332.5360.03-
Inventory1.54M30.64K34.19K39.13K35.77K27.72K00
Days Inventory Outstanding9.52K35.1715.714.078.948.32--
Other Current Assets99.58K14.22M309.03K135.95K71.2K3.34M00
Total Non-Current Assets11.28M16.35M15.92M10.57M9.22M13.8M18.16M15.17M
Property, Plant & Equipment346.59K4.26M7.09M5.38M4.03M3.17M1.85M0
Fixed Asset Turnover-0.09x0.08x0.17x0.38x0.41x0.23x-
Goodwill00000000
Intangible Assets1.47M1.41M1.31M964.86K880.26K752.71K147.35K0
Long-Term Investments7.39M7.09M7.11M4.08M4.16M9.74M16.1M15.1M
Other Non-Current Assets2.06M119.67K59.83K149.18K149.18K127.3K71.82K71.82K
Total Assets
31.56M▲ 0%
45.07M▲ 42.8%
23.95M▼ 46.9%
44.23M▲ 84.6%
21.91M▼ 50.5%
20.87M▼ 4.7%
20.64M▼ 1.1%
16.13M▼ 21.9%
Asset Turnover-0.01x0.02x0.02x0.07x0.06x0.02x-
Asset Growth %-42.82%-46.86%84.65%-50.47%-4.75%-1.09%-21.85%
Total Current Liabilities1.33M12.18M2.67M3.87M4.38M12.5M2.1M4.34M
Accounts Payable040.14K000000
Days Payables Outstanding-46.07------
Short-Term Debt480K10.11M0627.92K204.7K6.01M204.41K3.24M
Deferred Revenue (Current)01.24M000000
Other Current Liabilities0811.93K55.48K-627.92K-204.7K0-204.41K0
Current Ratio15.24x2.36x3.00x8.70x2.90x0.57x1.18x0.22x
Quick Ratio14.09x2.35x2.99x8.69x2.89x0.56x1.18x0.22x
Cash Conversion Cycle-932.27------
Total Non-Current Liabilities0143.87K6.43M2.21M23.85K530.78K3.16M14.18K
Long-Term Debt006.33M2.01M0500K3.06M0
Capital Lease Obligations0143.87K97.32K203.04K23.85K30.78K99.48K14.18K
Deferred Tax Liabilities00000000
Other Non-Current Liabilities00000000
Total Liabilities1.33M12.33M9.1M6.08M4.4M13.03M5.26M4.35M
Total Debt480K10.3M6.47M3.32M217.17K6.85M3.49M3.35M
Net Debt-15.77M-1.71M1.29M-174.98K-7.91M4.97M1.48M2.48M
Debt / Equity0.02x0.31x0.44x0.09x0.01x0.88x0.23x0.28x
Debt / EBITDA--------
Net Debt / EBITDA--------
Interest Coverage--2.32x-4.92x-81.66x-205.20x--87.51x-25.84x
Total Equity
30.23M▲ 0%
32.75M▲ 8.3%
14.85M▼ 54.6%
38.15M▲ 156.9%
17.51M▼ 54.1%
7.83M▼ 55.3%
15.38M▲ 96.4%
11.78M▼ 23.4%
Equity Growth %-8.33%-54.65%156.89%-54.12%-55.25%96.38%-23.44%
Book Value per Share10.0411.735.1212.105.002.193.402.16
Total Shareholders' Equity30.24M33.11M16.36M41.83M23.61M15.71M24.85M21.13M
Common Stock27.86M28.98M29.04M34.02M35.64M35.71M5355
Retained Earnings-2.55M-17.38M-37.56M-30.49M-55.54M-65.34M-68.16M-72.43M
Treasury Stock00000000
Accumulated OCI-367.78K-1.48M-5.55K53.3K-2.02K33.81K-10.62K89.16K
Minority Interest-14.04K-368.53K-1.51M-3.68M-6.1M-7.88M-9.46M-9.36M

APM Cash Flow Statement

Aptorum Group Limited (APM) cash flow — operating, investing & free cash flow history

Line itemDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24
Cash from Operations-5.78M-10.04M-13.38M-15.93M-14.65M-12.32M-7.72M-1.19M
Operating CF Margin %--2617.17%-2500.65%-1747.86%-950.17%-950.54%-1790.63%-
Operating CF Growth %--73.54%-33.35%-19.05%8.04%15.92%37.3%84.58%
Net Income-2.55M-15.13M-20.12M4.92M-27.11M-11.53M-4.34M-4.27M
Depreciation & Amortization58.9K682.29K1.3M1.33M1.19M1.21M1.13M255.05K
Stock-Based Compensation001.61M1.48M1.68M1.65M1.27M0
Deferred Taxes00-1.53M-24.46M7.96M000
Other Non-Cash Items-2.93M4.81M4.14M751.03K609.34K-5.05M-6.18M3.03M
Working Capital Changes-195.09K-389.73K1.22M45.55K1.02M1.4M407.07K-211.1K
Change in Receivables-48.01K-2.83K-37.72K-21.68K-16.5K-171.91K417.22K41.35K
Change in Inventory0-30.64K-3.54K-4.95K3.36K8.05K14.52K0
Change in Payables058.55K986.24K800.96K855.27K1.92M398.63K0
Cash from Investing12.8M-6.06M-108.06K1.84M16.51M2.44M624.77K58.62K
Capital Expenditures-3.06M-6.06M-1.11M-161.31K-137.78K-186.92K-3.02K0
CapEx % of Revenue-1581.51%206.88%17.7%8.93%14.42%0.7%-
Acquisitions0417.79K270.11K25.24M-113.83K015.38K58.62K
Investments--------
Other Investing-186.9K83.73K-70.11K1.05M-3.35M2.5M519.18K0
Cash from Financing9.08M25.48M-7.32M12.42M2.78M6.63M4.09M1.43K
Debt Issued (Net)480K16.06M-7.32M-4.36M-2.04M6.45M2.55M1.43K
Equity Issued (Net)1000K1000K01000K1000K5.36K1000K0
Dividends Paid000-755.51K0000
Share Repurchases00000000
Other Financing0-1.64M040.42K824.24K169.46K-54.53K0
Net Change in Cash
16.1M▲ 0%
9.38M▼ 41.7%
-20.81M▼ 321.9%
-1.67M▲ 92.0%
4.64M▲ 378.0%
-3.25M▼ 170.1%
-3.01M▲ 7.4%
-1.13M▲ 62.4%
Free Cash Flow
-8.84M▲ 0%
-16.1M▼ 82.1%
-14.49M▲ 10.0%
-16.09M▼ 11.1%
-14.79M▲ 8.1%
-12.51M▲ 15.4%
-7.73M▲ 38.2%
-1.19M▲ 84.6%
FCF Margin %--4198.68%-2707.53%-1765.56%-959.11%-964.96%-1791.32%-
FCF Growth %--82.08%10%-11.07%8.1%15.44%38.21%84.59%
FCF per Share-2.94-5.77-4.99-5.10-4.22-3.50-1.71-0.22
FCF Conversion (FCF/Net Income)2.27x0.68x0.72x-2.25x0.58x1.26x2.73x0.28x
Interest Paid00000000
Taxes Paid00000000

APM Key Ratios

Aptorum Group Limited (APM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric20172018201920202021202220232024
Return on Equity (ROE)-8.43%-47.1%-78.52%26.67%-90.01%-77.35%-24.34%-31.43%
Return on Invested Capital (ROIC)-29.52%-34.05%-57.87%-55.15%-60.57%-117.26%-53.59%-18.29%
Gross Margin-17.07%-48.4%-11.41%5.31%6.18%2.45%-
Net Margin--3868.04%-3491.81%775.31%-1624.38%-756.17%-654.88%-
Debt / Equity0.02x0.31x0.44x0.09x0.01x0.88x0.23x0.28x
Interest Coverage--2.32x-4.92x-81.66x-205.20x--87.51x-25.84x
FCF Conversion2.27x0.68x0.72x-2.25x0.58x1.26x2.73x0.28x
Revenue Growth--39.57%70.32%69.17%-15.95%-66.71%-100%

APM Frequently Asked Questions

Aptorum Group Limited (APM) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Aptorum Group Limited (APM) reported $0.4M in revenue for fiscal year 2024.

Aptorum Group Limited (APM) saw revenue decline by 100.0% over the past year.

Aptorum Group Limited (APM) reported a net loss of $7.1M for fiscal year 2024.

Dividend & Returns

Aptorum Group Limited (APM) has a return on equity (ROE) of -31.4%. Negative ROE indicates the company is unprofitable.

Aptorum Group Limited (APM) had negative free cash flow of $9.0M in fiscal year 2024, likely due to heavy capital investments.

Explore More APM

Aptorum Group Limited (APM) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.